You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

carfilzomib

Showing 26 - 50 of 227
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Anemia, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Atlanta, Columbus, Salt Lake City (drug, other,

Active, not recruiting
  • Anemia
  • +2 more
  • Carfilzomib
  • +3 more
  • Atlanta, Georgia
  • +2 more
Jan 28, 2023

Multiple Myeloma Trial in Torino (Carfilzomib, Cyclophosphamide, Dexamethasone)

Active, not recruiting
  • Multiple Myeloma
  • Carfilzomib
  • +2 more
  • Torino, Italy
    Fondazione EMN Italy Onlus
Mar 24, 2022

Multiple Myeloma Trial in United States (daratumumab, carfilzomib, lenalidomide)

Active, not recruiting
  • Multiple Myeloma
  • Basking Ridge, New Jersey
  • +6 more
Dec 28, 2022

Relapsed Refractory Multiple Myeloma Trial in India (Drug: Carfilzomib + Dexamethasone, Drug: Carfilzomib + Lenalidomide +

Active, not recruiting
  • Relapsed Refractory Multiple Myeloma
  • Drug: Carfilzomib + Dexamethasone
  • Drug: Carfilzomib + Lenalidomide + Dexamethasone
  • Hyderabad, Andhra Pradesh, India
  • +16 more
Dec 13, 2022

Neuroendocrine Cancer Trial in United States (Carfilzomib)

Completed
Has Results
  • Neuroendocrine Cancer
  • Carfilzomib
  • Denver, Colorado
  • +9 more
Jun 7, 2022

Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Seattle (Carfilzomib, Dexamethasone, Isatuximab)

Recruiting
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Carfilzomib
  • +3 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Aug 16, 2022

Multiple Myeloma Trial in Torino (Carfilzomib, Pomalidomide, Dexamethasone)

Active, not recruiting
  • Multiple Myeloma
  • Carfilzomib
  • +2 more
  • Torino, Italy
    Dipartimento di Biotecnologie Molecolari e Scienze per la Salute
Mar 24, 2022

Relapsed or Refractory Multiple Myeloma Trial (Forimtamig, Carfilzomib, Daratumumab)

Not yet recruiting
  • Relapsed or Refractory Multiple Myeloma
  • (no location specified)
Sep 20, 2023

Long-term KRd in Relapsed and/or Refractory Multiple Myeloma

Not yet recruiting
  • Multiple Myeloma in Relapse
  • Multiple Myeloma, Refractory
  • Carfilzomib
  • +2 more
  • (no location specified)
Aug 8, 2022

Highly Sensitized Prospective Kidney Transplant Recipients Trial in Durham (carfilzomib, belatacept, Bone marrow aspiration)

Recruiting
  • Highly Sensitized Prospective Kidney Transplant Recipients
  • carfilzomib
  • +2 more
  • Durham, North Carolina
    Duke Transplant Center, Duke University Medical Center
Jan 11, 2022

Multiple Myeloma Trial in United States (Carfilzomib, Pomalidomide, Dexamethasone)

Terminated
  • Multiple Myeloma
  • Carfilzomib
  • +2 more
  • Atlanta, Georgia
  • +8 more
Jul 28, 2022

Multiple Myeloma Trial in Worldwide (Carfilzomib Lenalidomide Dexamethasone, Isatuximab Carfilzomib Lenalidomide Dexamethasone)

Active, not recruiting
  • Multiple Myeloma
  • Carfilzomib Lenalidomide Dexamethasone
  • Isatuximab Carfilzomib Lenalidomide Dexamethasone
  • Ostrava, Czechia
  • +6 more
Jul 26, 2022

Multiple Myeloma in Relapse Trial in Finland, Sweden (Carfilzomib for Inj 60 milligram (MG), Elotuzumab 400 MG, Dexamethasone)

Active, not recruiting
  • Multiple Myeloma in Relapse
  • Carfilzomib for Inj 60 milligram (MG)
  • +2 more
  • Helsinki, Finland
  • +7 more
Mar 14, 2022

Multiple Myeloma in Relapse Trial in Aurora (Selinexor, Pomalidomide, Daratumumab)

Recruiting
  • Multiple Myeloma in Relapse
  • Aurora, Colorado
    University of Colorado Hospital
Jan 31, 2023

Hematologic Malignancies, Relapse, GVHD Trial in Ann Arbor (Carfilzomib, Tacrolimus)

Completed
Has Results
  • Hematologic Malignancies
  • +2 more
  • Ann Arbor, Michigan
    University of Michigan Hospital
Dec 3, 2021

Refractory Multiple Myeloma Trial in United States (selinexor, carfilzomib, dexamethasone)

Recruiting
  • Refractory Multiple Myeloma
  • Scottsdale, Arizona
  • +4 more
Apr 1, 2022

Relapsed Solid Tumors, Refractory Solid Tumors, Relapsed Leukemia Trial in Canada, United States (Carfilzomib, Cyclophosphamide,

Recruiting
  • Relapsed Solid Tumors
  • +3 more
  • Carfilzomib
  • +2 more
  • Phoenix, Arizona
  • +7 more
Apr 12, 2022

Multiple Myeloma Trial in New Haven (Guided Lesion Biopsies, Standard Lesion Biopsies)

Completed
  • Multiple Myeloma
  • Guided Lesion Biopsies
  • Standard Lesion Biopsies
  • New Haven, Connecticut
    Yale Cancer Center
Feb 23, 2022

Multiple Myeloma Trial in Washington, Hackensack (Selinexor 60 MG, Selinexor 80 MG, Selinexor 100 MG)

Recruiting
  • Multiple Myeloma
  • Selinexor 60 MG
  • +6 more
  • Washington, District of Columbia
  • +1 more
Feb 3, 2022

Multiple Myeloma Trial in Charlotte (Carfilzomib, Lenalidomide, Dexamethasone, Belantamab Mafodotin)

Recruiting
  • Multiple Myeloma
  • Carfilzomib, Lenalidomide, Dexamethasone, Belantamab Mafodotin
  • Charlotte, North Carolina
    Levine Cancer Institute
Nov 17, 2021

Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Seattle (Carfilzomib, Chemosensitivity Assay,

Terminated
Has Results
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Carfilzomib
  • +4 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
May 6, 2022

Smouldering Myeloma Trial in Worldwide (Carfilzomib, Dexamethasone, Lenalidomide)

Recruiting
  • Smouldering Myeloma
  • Carfilzomib
  • +2 more
  • Brno, Czechia
  • +15 more
Mar 22, 2022

Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in United States (drug, biological, other)

Recruiting
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Carfilzomib
  • +4 more
  • Des Moines, Iowa
  • +8 more
Jan 12, 2023

Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Rochester (Carfilzomib, Dexamethasone, Pomalidomide)

Recruiting
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Carfilzomib
  • +5 more
  • Rochester, Minnesota
    Mayo Clinic in Rochester
Jun 3, 2022

Plasma Cell Myeloma Trial in Atlanta (Carfilzomib, Dexamethasone, Pomalidomide)

Recruiting
  • Plasma Cell Myeloma
  • Carfilzomib
  • +2 more
  • Atlanta, Georgia
    Emory University Hospital/Winship Cancer Institute
Oct 5, 2021